RESTON, Va., Aug. 11, 2014 /PRNewswire/ -- Leidos (NYSE: LDOS), a national security, health and engineering solutions company, is a Platinum Sponsor of the 34th National Veterans Wheelchair Games scheduled for Aug. 12-17 in Philadelphia, Pa. The Games are presented by Paralyzed Veterans of America and the U.S. Department of Veterans Affairs.
As the largest annual wheelchair sports competition in the world, the Games offer 17 different sports to veterans who use wheelchairs due to spinal cord injuries, amputations and neurological diseases. The Games promote rehabilitation through rigorous competition in events including weightlifting, basketball, rugby, softball, handcycling and others. A special "Kids Day" program allows children with disabilities to meet the athletes and be introduced to wheelchair sports. While past Games have produced national and world-class champions, the Games also provide opportunities for newly injured veterans to gain sports skills and be exposed to other wheelchair athletes, while also promoting a spirit of healthy activity and camaraderie.
"This is our fifth consecutive sponsorship of the National Veteran Wheelchair Games, and we couldn't be prouder of supporting the games and giving back to the veterans who have sacrificed so much for our safety and the freedom of our nation," said Steve Comber, President of Leidos Health. "The games and the entire week of events give these incredible men and women an opportunity to enjoy friendly competition and demonstrate that anything is possible, if you set your mind to it."
As part of the Leidos sponsorship, the company donated $50,000 to help offset the cost of the event. Throughout the year, Leidos has pledged nearly $100,000 to support various paralyzed veteran fundraising activities, including the PVA golf tournament and its Mission ABLE Awards Gala. For more information on the games, visit http://www.pva.org/sports_games.
About Leidos Health As a leader for more than 25 years in the healthcare industry, Leidos Health fuses some of the world's most advanced technologies with the brightest minds in science, research and consulting. Today, Leidos Health is focused on developing next-generation solutions in areas such as biomedical research, public health and health analytics to turn data into actionable information for clinicians and their patients. From leading groundbreaking medical research to fighting diseases such as cancer, AIDS and malaria, to implementing and optimizing electronic health records that enhance the research process and improve critical efficiencies – Leidos Health's passion to improve patient care and reduce costs is helping to transform healthcare. For more information, visit www.Leidos.com/health.
About Leidos Leidos is a FORTUNE 500® science and technology solutions leader working to address some of the world's toughest challenges in national security, health and engineering. The Company's 22,000 employees support vital missions for our government and the commercial sector, develop innovative solutions to drive better outcomes and defend our Nation's digital and physical infrastructure from 'new world' threats. Headquartered in Reston, Va., Leidos reported annual revenues of approximately $5.77 billion for its fiscal year ended January 31, 2014 after giving effect to the spin-off of the company's technical services and information technology business. For more information, visit www.Leidos.com.
Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended January 31, 2014, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.